A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor, in patients with advanced or metastatic solid tumors

AFNT-211 - Affini-T Therap

https://www.abstractsonline.com/pp8/#!/20273/presentation/10470

Soumit Basu1; Binaish Khan1; Francis Payumo1; E. Gabriela Chiorean2; Zhubin Gahvari3; J. Randolph Hecht4; Michael Hurwitz5; Rom Leidner6; Heinz-Josef Lenz7; Meredith Pelster8; Salman Punekar9; Adam Schoenfeld10; Dan Zhao11; Dirk Nagorsen1

Mar 26, 2025